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1. ABSTRACT 12 
This paper presents a systematic review of human studies investigating the effect of altering 13 
dietary omega-3 (n-3) alpha-linolenic acid (ALA) and omega-6 (n-6) linoleic acid (LA) 14 
intakes on n-3 long-chain polyunsaturated fatty acid (LCPUFA) status in adult humans. The 15 
results suggest that it is possible to increase n-3 LCPUFA status by reducing LA and/or 16 
increasing ALA intake in humans, although decreasing LA intake to below 2.5%E may be 17 
required to specifically increase levels of the n-3 LCPUFA docosahexaenoic acid (DHA). 18 
The majority of studies in this area to date have been relatively poor in quality, which limits 19 
the ability to draw robust conclusions, and we present a series of recommendations to 20 
improve the quality of future studies in fatty acid nutrition in humans.  21 
 22 
KEY WORDS: ALA, LA, diet, human, n-3 LCPUFA, DHA, EPA, dietary intervention 23 
.   24 
  25 
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2. INTRODUCTION 26 
The n-3 long chain fatty acids (LCPUFA) eicosapentaenoic acid (EPA, 20:5 n-3) and 27 
docosahexaenoic acid (DHA, 22:6 n-3) have a number of reported  health benefits in humans, 28 
in particular in relation to cardiovascular [1] and inflammatory [2, 3] conditions. This has led 29 
to recommendations from health agencies world-wide to increase dietary intake of these fatty 30 
acids [4]. EPA and DHA are mainly derived pre-formed through consumption of either fish 31 
or fish-oil supplements. However, they can also be synthesised de novo through conversion 32 
of the plant-derived short-chain n-3 PUFA precursor, alpha-linolenic acid (ALA, 18:3 n-3). It 33 
has been suggested that increasing dietary intake of ALA could provide an alternative to fish 34 
or fish-oil intake for increasing n-3 LCPUFA status in humans, although the efficiency of this 35 
process in adult humans is generally low [5].  36 
 37 
The levels of n-6 PUFA also have the potential to impact on n-3 LCPUFA status. This is due 38 
to the competition between n-6 and n-3 PUFA for both enzymatic conversion of the short-39 
chain precursors, linoleic acid (LA, 18:2n-6) and ALA, to their respective long-chain 40 
derivatives, and for incorporation into cell membranes [6]. LA competes with ALA for the 41 
desaturase and elongase enzymes required for its conversion to EPA and DHA, and as a 42 
result, high levels of LA in the background diet reduce the efficiency of endogenous 43 
synthesis of n-3 LCPUFA  from ALA [6]. In addition, since the incorporation of n-3 44 
LCPUFA into the cellular membrane is required for them to mediate certain biological 45 
effects, increased competition from n-6 PUFA can affect the relationship between n-3 PUFA 46 
intake and tissue n-3 PUFA status [7, 8]. It has therefore been suggested that excessive 47 
intakes of dietary n-6 PUFA may limit the ability of ALA and n-3 LCPUFA consumed in the 48 
diet to increase n-3 LCPUFA status, and that reducing n-6 PUFA intake could potentially 49 
improve n-3 LCPUFA status without a need to increase n-3 LCPUFA intake [8]. This has 50 
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particular significance given the substantial increases in n-6 PUFA intakes in Western 51 
countries world-wide over the past century [9, 10].  52 
 53 
Animal studies have highlighted that levels of n-3 LCPUFA in tissues can be regulated by 54 
simply altering the balance of LA and ALA in the diet and that a dose-response relationship 55 
exists between dietary ALA intake and the n-3 LCPUFA content of blood and tissues[11-13]. 56 
There is also evidence that reducing the LA content of infant formulas increases the 57 
efficiency of cellular DHA incorporation in human infants [14]. However, there have been 58 
comparatively few studies evaluating the effects of increasing dietary ALA and/or decreasing 59 
n-6 PUFA intake on n-3 LCPUFA status in adult humans, and these results have yet to be 60 
systematically evaluated.  61 
 62 
This paper presents a review of human studies investigating the effect of altering dietary 63 
ALA and LA intakes on n-3 LCPUFA status. In assessing these studies, we have identified a 64 
number of common methodological issues, and therefore include a series of 65 
recommendations to improve the quality of future studies in fatty acid nutrition in humans.  66 
 67 
3. METHODS 68 
3.1 Search strategy 69 
MEDLINE (www.ncbi.nlm.nih.gov/pubmed) and EMBASE (www.embase.com) databases 70 
were searched for relevant articles using the search terms “alpha linolenic acid” OR “a-71 
linolenic acid” OR “ALA” or “linoleic acid” or “omega 6 fatty acid” OR “n-6 fatty acid” 72 
AND “diet”. The search was restricted to human studies. No language or date restrictions 73 
were imposed. The reference lists of eligible articles identified by the search were also 74 
checked to reveal other potentially relevant articles. The last literature search was conducted 75 
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in August 2014 and the search engines were set up to email new publications identified by the 76 
search on a weekly basis.  77 
 78 
3.2 Selection of articles 79 
Studies were eligible for inclusion if they were dietary interventions involving adult, non-80 
pregnant participants that specifically aimed to alter dietary intake of LA and/or ALA. The 81 
studies had to report LA and ALA intakes as a % of energy (%E) and include measures of 82 
EPA and DHA content in plasma or erythrocyte phospholipids before and after the dietary 83 
intervention. Two review authors (KW and EM) assessed the titles, abstracts, and where 84 
necessary, the full text of the article for study eligibility, a third author (BM) was consulted to 85 
resolve any discrepancies.  86 
 87 
3.3 Studies identified by search strategy 88 
The initial search identified 674 references after exclusion of duplicates. Additional 89 
publications were identified from references listed in original papers. This secondary search 90 
added 16 potentially relevant papers bringing the total to 690. The title and abstract of each 91 
reference was initially reviewed. Based on this information; 640 references were assessed as 92 
not fulfilling the inclusion criteria and were hence excluded at this stage. The full-text of the 93 
remaining 50 articles were reviewed in relation to the inclusion criteria. The process of article 94 
selection and reasons for exclusion are shown in Figure 1.  95 
 96 
Data from each included study were independently extracted by 1 review author (KW) and 97 
then verified by another (EM). Where all details could not be clearly identified from the 98 
article, the authors were contacted for clarification. Three authors did not respond to this 99 
request and these studies were therefore excluded from the systematic review [15-17].  100 
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4. RESULTS 101 
4.1 Description of included studies 102 
Data from 20 publications reporting data from 18 separate trials were included in this review, 103 
dating from 1994 to 2013.  All studies were randomized controlled trials apart from one open 104 
label clinical trial where participants acted as their own control [18]. The included studies are 105 
summarized in Table 1 with extracted information on country, gender and number of 106 
participants, description of intervention including the levels of LA and ALA as a percentage 107 
of energy, LA:ALA ratio, % total fatty acid results (ALA, EPA and DHA) for baseline (if 108 
reported) and post-intervention in plasma phospholipids or erythrocytes.  109 
 110 
The dietary interventions in these studies were categorized based on the approach applied to 111 
improve n-3 LCPUFA status, i.e. increasing intake of the short-chain n-3 PUFA, ALA, to 112 
provide more substrate for conversion to n-3 LCPUFA, reducing intake of the short-chain n-6 113 
PUFA, LA, to reduce competition for ALA conversion/n-3 LCPUFA cellular incorporation 114 
or a combination of both. Alternative dietary approaches were placed in a fourth sub-115 
category. 116 
 117 
The characteristics of the sub-categories were:  118 
 (1) Increasing dietary intake ALA to between 1.1 and 6.3%E while maintaining dietary LA 119 
intake in the normal range (4.3-7.3%E) (n=9).  120 
(2) Decreasing dietary intake of LA to between 2.4 and 3.9%E while maintaining dietary 121 
ALA intake in the normal range (0.4-0.7%E) (n=7)  122 
(3) Increasing ALA intake to between 1.6 and 6.3%E in conjunction with decreased dietary 123 
LA intake (2.5%-4.6%E) (n=7) and  124 
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(4) Decreasing ALA intake to between 0.01 and 0.5%E in conjunction with either decreased 125 
or maintained LA intake (2.0%-6%E) (n=6) 126 
 127 
The lowest LA:ALA diet ratio in all trials was 1:1 and the highest was 26:1.  The number of 128 
dietary interventions in each category is summarized in Table 2 (note that some trials 129 
included more than one category of dietary intervention).  130 
 131 
4.2 Intervention 132 
The majority of trials in all categories used capsules, liquid oil or specially produced 133 
foodstuffs, e.g. margarines, salad dressings, bread and cakes, with a pre-defined fatty acid 134 
composition against a background of either individually designed diets or standard diets to 135 
achieve the desired changes in dietary fatty acid intakes. The majority of the trials (15/20) 136 
were conducted in free living individuals who were provided with fortified foods to add to 137 
their normal diet and/or were advised on foods to consume and/or to avoid at home. 138 
Individually designed diets which were kilojoule and nutrient controlled according to energy 139 
requirements were used in the remaining 5 studies [16, 19-22].  140 
 141 
Flaxseed/linseed oil (LA, 16%; ALA, 57% of total fatty acids) was the oil most commonly 142 
used to increase dietary ALA, while sunflower (LA, 64% of total fatty acids) and canola (LA, 143 
20%; ALA, 10% of total fatty acids) oils were used to increase dietary n-6 in the majority of 144 
studies. These oils were either provided in the form of capsules or added to foods to modify 145 
the dietary fat profile. One study used macadamia oil (LA, 1-3%; ALA, 1-2% of total fatty 146 
acids) in the low LA dietary intervention [18]. Studies which aimed to reduce n-6 PUFA 147 
intake that did not utilize individually prescribed diets provided specific instructions to 148 
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participants regarding foods to avoid at home and eating out during the low LA intervention 149 
phase.  150 
Thirteen studies [16, 18-21, 23-30] allowed fish during the high ALA/low LA dietary 151 
intervention, while 7 studies excluded fish [22, 31-36]. Two studies excluded all meat sources 152 
from the diet throughout the trial [33, 37].  153 
4.3 Method of recording dietary intake 154 
A number of methods were used to assess dietary intake in these studies. The use of a 155 
weighed food diary was reported in 7 of the 20 trials [18, 22, 23, 30-33]. However, of these, 156 
diaries were kept only for one week during the intervention period in three studies [22, 31, 157 
32] and in one study the length of time the diaries were kept was not reported [30]. Six 158 
studies stated that dietary intake was assessed using food diaries/records, however no details 159 
of the methodology were provided, and it was unclear whether or not the foods in these 160 
records were weighed [25, 26, 29, 34-36]. The remaining studies used food frequency 161 
questionnaires, diet history interviews and 24 hour food recalls to assess dietary intake [16, 162 
20, 21, 24, 26-28]. 163 
 164 
4.4 Sample population type, sample size and intervention duration 165 
The studies included in this review were undertaken across a range of countries including the 166 
USA, Australia, United Kingdom and the Netherlands (Table 1).  Sample sizes ranged from 8 167 
to 605 participants with the majority of studies (17/20) having less than 74 participants, and 168 
with some of the intervention groups having a sample size as small as 8 [25]. Participants 169 
were aged between 19 and 65 years with three studies including participants in their 70s. Of 170 
the included studies, 5 included only male participants [19, 23, 25, 33, 34], 1 included only 171 
female participants [21], while the remaining studies included both sexes. The majority of 172 
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studies included healthy volunteers with only three  studies including participants with 173 
coronary disease, rheumatoid arthritis, or chronic daily headaches [16, 26, 27, 29]and one 174 
study only including post-menopausal women with high circulating levels of testosterone 175 





. The majority of studies (14/20) reported no changes between or 177 
within groups for body mass index (BMI) with two studies reporting differences in the body 178 
weight change across the trial period between treatment groups [21, 28]. The dietary 179 
interventions varied in length from 4 weeks to 5 years with between 4 and 12 weeks being the 180 
most common (17/20 studies). Of the studies reported in this review, 12 reported fatty acid 181 
content of plasma phospholipids pre- and post-intervention, 6 reported fatty acid status in 182 
erythrocyte phospholipids and 2 reported both.  183 
 184 
4.5 Effects on n-3 LCPUFA status 185 
The impact of the dietary intervention on EPA and DHA status for the 4 different 186 
intervention categories is summarized in Table 2.  Six of the 9 studies which increased 187 
dietary ALA while maintaining LA intake reported a significant increase in EPA status [22, 188 
24, 25, 28, 32, 33], but none reported increases in DHA status. Five of the 7 studies which 189 
decreased LA while maintaining ALA intake reported a significant increase in EPA status 190 
[16, 22, 26, 29, 32]and three reported increases in both EPA and DHA [16, 26, 29] . Six of 191 
the 7 studies which both increased ALA and decreased LA intake reported a significant 192 
increase in EPA [23, 24, 26-29, 34], and 3 reported increases in both EPA and DHA status 193 
[26, 27, 29].  Only one of the 6 studies which reduced ALA whilst maintaining or reducing 194 





5. DISCUSSION 198 
A review of the current literature suggests that most of the studies in adult humans in which 199 
ALA intake was increased reported increases in EPA status at the end of the intervention 200 
period, whereas only studies that reduced LA intake reported increases in DHA status. The 201 
results of these existing studies therefore provide evidence that it is possible to improve n-3 202 
LCPUFA status in humans without increasing n-3 LCPUFA intake, however whether these 203 
effects are sufficient to provide clinical benefits or to overcome the effects of long-term 204 
habitual dietary intake, remains to be determined. 205 
 206 
While the sample sizes were generally small, all but 3 studies reported that increased ALA 207 
intake to between 1.1 and 6.3 %E, compared to ~0.6%E in the typical Western diet, was 208 
associated with a significant increase in EPA status. There was also some suggestion of a 209 
dose-response relationship, with the 2 studies which increased ALA intake to the greatest 210 
extent (3.4%E and 6.3%E) demonstrating the greatest increases in EPA status [24, 33]. There 211 
was also considerable variability, however, in the proportional increase in EPA between 212 
studies, ranging between 33% and 90% in studies with relatively modest increases in ALA 213 
intakes (from ~0.6% to ~1.5%E).  This is consistent with previous studies suggesting that the 214 
efficiency of ALA conversion in humans is influenced by a range of factors, including the 215 
background diet, sex and genetics [38], and suggests that increasing ALA intakes may not 216 
necessarily be an appropriate strategy for increasing EPA status in all individuals. The results 217 
of the studies in this review also suggest that increasing ALA intake is not an effective 218 
strategy for increasing DHA status in adult humans. This is consistent with studies in rodents, 219 
which have reported that while the EPA content of blood and tissues increases linearly with 220 
increasing ALA intake, DHA content plateaus at relatively low dietary ALA intakes (~1%E) 221 
[11, 12]. This is not unexpected given that the delta-6-desaturase is used once in the synthesis 222 
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of EPA from ALA, but twice in the synthesis of DHA, such that increasing the amount of 223 
ALA in the system effectively limits the availability of the desaturase enzyme for converting 224 
EPA through to DHA[6].  225 
 226 
The 3 studies that failed to demonstrate an increase in EPA intake in response to increased 227 
ALA intake all had methodological issues which complicate the interpretation of the results. 228 
Two of the studies did not include a run-in period prior to the start of the dietary intervention 229 
[35, 36]. This is particularly important given that all three of these studies also excluded fish 230 
from the diet. Although dietary intake of n-3 LCPUFA during the intervention period was not 231 
reported, it seems reasonable to assume that the exclusion of fish would have resulted in 232 
lower EPA and DHA intakes during the intervention period. Thus, any increase in EPA 233 
synthesis due to increases in ALA intakes may have been counteracted by decreases in EPA 234 
intake over the same period. Notably, the one study that did include a run-in period, although 235 
it failed to detect a significant increase in EPA status as a result of 6 weeks on a diet 236 
containing 3.23%E ALA, did report increases in EPA status from 0.6 to 1.0% (66%) [31] 237 
which was similar in magnitude to that reported in other studies with similar doses. It is 238 
therefore possible that the small number of subjects (n=13) and mixture of males and 239 
females, which are known to have different capacities for ALA conversion [38], may have 240 
increased variability and limited the statistical power of the study to detect differences 241 
between groups.  242 
 243 
The fact that, of the 7 studies which decreased LA intake without a concomitant increase in 244 
ALA, 5 reported an increase in EPA status and 3 also demonstrated increases in DHA status, 245 
is consistent with the view that reducing LA intake is an effective strategy for increasing the 246 
incorporation of pre-formed n-3 LCPUFA and/or conversion of ALA to its long-chain 247 
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derivatives in humans, by reducing competition for these processes. The one study that did 248 
not report an increase in EPA status following a low LA diet was conducted in a very specific 249 
population, i.e. postmenopausal women with low estrogen and high circulating testosterone 250 
concentrations [21]. Since estrogen has been implicated in the higher capacity for ALA 251 
conversion in females compared to males [5], it is possible that the low estrogen and high 252 
testosterone in these women reduced their efficiency for ALA conversion, despite the 253 
reduced competition from LA. Interestingly, this same study did report an increase in DHA 254 
status following the low LA diet, however it is difficult to determine the extent to which this 255 
was due to the reduction in LA intake, since the authors also reported that fish intake 256 
increased 2-fold during the intervention period compared to baseline. This latter example 257 
highlights the importance of ensuring that the intake of fatty acids other than those which are 258 
the subject of study are maintained at a constant level during the intervention period.  259 
The results of the human studies conducted to date suggest that the most effective strategy for 260 
increasing n-3 LCPUFA was a combined approach involving both an increase in ALA and 261 
decrease in LA intake, with 6 of the 7 studies which took this approach reporting significant 262 
increases in EPA status at the end of the intervention. The one study that was not successful 263 
with this intervention was conducted on a small group of males (n=16)[19], and it is possible 264 
that the failure to detect an effect was due to the lower efficiency of conversion of ALA to 265 
EPA in males compared to females [38]. In addition, the study involved a cross-over design 266 
in which the control and low LA/high ALA diets were fed to the same individuals over 2 267 
separate 56-day periods, but failed to include a wash-out period between the diets. This 268 
makes it difficult to draw clear conclusions, since carry-over effects of the first diet are likely 269 
to have impacted on the response of the individual to the subsequent diet.  270 
While the combination of reduced LA and increased ALA intake appears to be effective at 271 
increasing EPA, the current evidence suggests that its efficacy in increasing DHA status may 272 
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be more limited. The three studies in this intervention category which reported increases in 273 
DHA both included fish in the diet [26, 27, 29]. In addition, one of these studies reported that 274 
fish and shellfish intakes actually increased during the intervention [27]. Thus, it is 275 
impossible to attribute the increased DHA status solely to the low LA/high ALA diet in this 276 
study. The only other studies to report an increase in DHA status [26, 29] had the greatest 277 
reduction in LA intake (from 7.4%E to 2.4%E), possibly indicating that this degree of 278 
reduction in LA intake is required in order to reduce competition to the extent that DHA, as 279 
well as EPA, synthesis/incorporation is enhanced. This is supported by the fact that the only 280 
study to report an increase in EPA and DHA status in response to a dietary intervention in 281 
which both ALA and LA intakes were reduced, was one which achieved a dietary LA intake 282 
of ~2.0%E, compared to 6%E in the pre-intervention period[18].  283 
 284 
5.1 Methodological Limitations and Recommendations for Future Studies 285 
5.1.1Accurate measures of dietary intake  286 
Results from dietary intervention studies are highly dependent on capturing actual dietary 287 
intake and participant’s compliance with the prescribed diet, both of which are notoriously 288 
difficult to capture in free-living humans. Less than half of the reviewed studies used a 289 
weighed food record, regarded as the gold standard in relation to assessing dietary intakes in 290 
humans [39], and where it was applied it was typically only done during a single week of the 291 
intervention period [22, 31, 32]. Thus, our recommendation for future studies is that 292 
information on dietary intake be collected using a weighed food diary both before and for 293 
each week of the dietary intervention period, in order to provide the most robust information 294 
regarding dietary fatty acid composition. In addition, the use of databases with accurate and 295 
up-to-date information on the fatty acid composition of foods is essential to ensuring the 296 




5.1.2 Maintaining consistency in the composition of the background diet  299 
In several studies included in this review the intake of fatty acids other than ALA and/or LA 300 
were also altered during the intervention period, making it difficult to attribute the changes in 301 
fatty acid status solely to the effects of altered dietary ALA/LA. This was particularly notable 302 
in the cases of studies in which participants were instructed to exclude fish from their diet 303 
during the intervention period, or in which the participant’s intake of fish/seafood actually 304 
increased during the ALA/LA dietary intervention. In addition, only four of the nineteen 305 
studies included a run-in period prior to the dietary intervention, or wash-out periods in cross-306 
over designs. Thus, to ensure that the effects of alterations to dietary ALA and/or LA on 307 
tissue fatty acid composition, it is essential to ensure that the intake of other fatty acids, in 308 
particular the n-3 LCPUFA, remains constant during the ALA/LA dietary intervention and 309 
that appropriate run-in periods are applied prior to the intervention where this is not the case.   310 
 311 
The majority of studies included in this review included small numbers of participants, and 312 
no study provided any justification for the sample size used or indication if they provided 313 
sufficient statistical power to limit type 1 errors. In addition, the majority of these studies 314 
included both male and female participants, and did not assess the results separately by sex. 315 
This is significant given the well-established differences in fatty acid metabolism between 316 
males and females, in particular the ~2.5 fold greater efficiency for ALA conversion in 317 
females compared to males [38]. Thus, our recommendation is for future studies that a 318 
sample size calculation be conducted before recruitment, and that males and females are 319 




5.2 Conclusion 322 
In summary, our systematic review of the existing literature suggests that it is possible to 323 
increase  EPA, and to some extent DHA, status by reducing LA and/or increasing ALA 324 
intake in humans, although the magnitude of these changes are arguably substantially less 325 
than those achieved with dietary n-3 LCPUFA supplementation. The most effective strategy 326 
for improving n-3 LCPUFA status appears to be a combination of increased ALA and 327 
reduced LA intakes, although it appears that decrease in LA intake to below 2.5%E may be 328 
required to successfully increase DHA status.  329 
Overall, the majority of studies in this area to date have been relatively poor in quality, which 330 
limits the ability to draw robust conclusions.  We have made a number of recommendations 331 
for improving the quality of fatty acid trials, including undertaking sample size calculations 332 
to ensure sufficient statistical power, separating males and females in the analysis, ensuring 333 
that the fatty acid composition of the background diet does not change during the intervention 334 
period and allowing for appropriate ‘wash-out’ and ‘run-in’ periods where this is not the case, 335 
e.g. where fish will be excluded. 336 
 337 
In conclusion, while the current data support the suggestion that n-3 LCPUFA status in 338 
humans can be increased in the absence of increased n-3 LCPUFA intake, there is a need for 339 
well-controlled and adequately powered studies in males and females in order to evaluate 340 
whether these diets could be a viable alternative to n-3 LCPUFA supplementation for 341 
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